Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma

Journal of Pathology

Volumn 215, Issue 3, 2008, Pages 222-230

  Kloth, J N ^a   Gorter, A ^a   Fleuren, G J ^a   Oosting, J ^a   Uljee, S ^a   Ter Haar, N ^a   Dreef, E J ^a   Kenter, G G ^a   Jordanova, E S ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Carcinoma; Cervix; Gene expression profiling; Human leukocyte antigen; Immunohistochemistry; Loss of heterozygosity; Quantitative real time PCR

Indexed keywords

ACUTE PHASE PROTEIN; BETA2 INTEGRIN; CC CHEMOKINE RECEPTOR LIKE 2; CXC CHEMOKINE LIGAND 3; CXCL2 CHEMOKINE; DEFENSIN BETA 106A; FYN BINDING PROTEIN; GRB2 RELATED ADAPTOR PROTEIN 2; HLA A ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA C ANTIGEN; INTERLEUKIN 18 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 21; INTERLEUKIN 28 RECEPTOR ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 3; PROTEIN KCNN4; PROTEIN NMI; PROTEIN OAS1; PROTEIN OAS2; PROTEIN OASL; PROTEIN ULRA2; SERINE PROTEINASE INHIBITOR; SERPIN A1; SERPIN A3; TOLL LIKE RECEPTOR 8;

ACUTE PHASE RESPONSE; ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; INFLAMMATION; LYSIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; UPREGULATION; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ALPHA 1-ANTITRYPSIN; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERPINS; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 46849084589     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2347     Document Type: Article

References (32)

1. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1-17.
2. Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F, et al. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis 1997;175:927-931.
3. Scott M, Stites DP, Moscicki AB. Th1 cytokine patterns in cervical human papillomavirus infection. Clin Diagn Lab Immunol 1999;6:751-755.
4. Man S. Human cellular immune responses against human papillomaviruses in cervical neoplasia. Expert Rev Mol Med 1998;1998:1-19.
5. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin invest 2007;117:1175-1183.
6. Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F. Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 2007;601:123-131.
7. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 2000;191:961-976.
8. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 2006;117:433-442.
9. Schellekens MC, Dijkman A, Aziz MF, Siregar B, Cornain S, Kolkman-Uljee S, et al. Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. Gynecol Oncol 2004;93:49-53.
10. Hazelbag S, Gorter A, Kenter GG, van den Broek L, Fleuren G. Transforming growth factor-betal induces tumor stroma and reduces tumor infiltrate in cervical cancer. Hum Pathol 2002;33:1193-1199.
11. Ruiter DJ, Ferrier CM, van Muijen GN, Henzen-Logmans SC, Kennedy S, Kramer MD, et al. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Eur J Cancer 1998;34:1334-1340.
12. Corver WE, Ter Haar NT, Dreef EJ, Miranda NF, Prins FA, Jordanova ES, et al. High-resolution multi-parameter DNA flow cytometry enables detection of tumour and stromal cell subpopulations in paraffin-embedded tissues. J Pathol 2005;206:233-241.
13. Haven CJ, van Puijenbroek M, Karperien M, Fleuren GJ, Morreau H. Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J Pathol 2004;202:86-94.
14. Kloth JN, Fleuren GJ, Oosting J, De Menezes RX, Eilers PH, Kenter GG, et al. Substantial changes in gene expression of Wnt, MAPK and TNF-alpha pathways induced by TGF-betal in cervical cancer cell lines. Carcinogenesis 2005;26:1493-1502.
15. Huber W, Gentleman R. Matchprobes: a Bioconductor package for the sequence-matching of microarray probe elements. Bioinformatics 2004;20:1651-1652.
16. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.
17. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990;9:811-818.
18. Goeman JJ, van de Geer SA, De Kort F, van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 2004;20:93-99.
19. Vandesompele J, De Preter K, Pattyn F, Poppe B, van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3(7):0034.11.
20. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nature Rev Cancer 2004;4:11-22.
21. Allgayer H, Babic R, Grutzner KU, Beyer BC, Tarabichi A, Schildberg FW, et al. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis 1998;16:62-73.
22. Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R. An evaluation of the prognostic significance of alpha-1-antitrypsin expression in adenocarcinomas of the lung: an immunohistochemical analysis. Br J Cancer 1992;65:300-302.
23. Karashima S, Kataoka H, Itoh H, Maruyama R, Koono M. Prognostic significance of alpha-1-antitrypsin in early stage of colorectal carcinomas. Int J Cancer 1990;45:244-250.
24. Zelvyte I, Stevens T, Westin U, Janciauskiene S. Alpha1-antitrypsin and its C-terminal fragment attenuate effects of degranulated neutrophil-conditioned medium on lung cancer HCC cells in vitro. Cancer Cell Int 2004;4:7.
25. Laine A, Leroy A, Hachulla E, Davril M, Dessaint JP. Comparison of the effects of purified human alpha 1-antichymotrypsin and alpha 1-proteinase inhibitor on NK cytotoxicity: only alpha 1-proteinase inhibitor inhibits natural killing. Clin Chim Acta 1990;190:163-173.
26. Poe M, Blake JT, Boulton DA, Gammon M, Sigal NH, Wu JK. et al. Human cytotoxic lymphocyte granzyme B. Its purification from granules and the characterization of substrate and inhibitor specificity. J Biol Chem 1991;266:98-103.
27. Takada S, Tsuda M, Mitomi T, Nakasaki H, Noto T, Ogoshi K, et al. Analysis of the tissue and cellular localization of alpha-1-antichymotrypsin by an immunohistochemical technique. Gann 1982;73:742-747.
28. Tahara E, Ito H, Taniyama K, Yokozaki H, Hata J. Alpha 1-antitrypsin, alpha 1-antichymotrypsin, and alpha 2-macroglobulin in human gastric carcinomas: a retrospective immunohistochemical study. Hum Pathol 1984;15:957-964.
29. Shimizu T, Pommier Y. DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies. Exp Cell Res 1996;226:292-301.
30. Emoto T, Nakamura K, Nagasaka Y, Numa F, Suminami Y, Kato H. Alpha 1-antichymotrypsin inhibits chymotrypsin-induced apoptosis in rat hepatoma cells. Apoptosis 1998;3:155-160.
31. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 2008;57:197-206.
32. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997;18:89-95.